title: Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk.
authors.affiliation: Reading Health SystemReading, Pennsylvania, USA.
authors.forename: Anthony A
authors.initials: AA
authors.lastname: Donato
mesh_terms: D002318:Cardiovascular Diseases; D003924:Diabetes Mellitus, Type 2; D003925:Diabetic Angiopathies; D004763:Glucagon-Like Peptides; D006801:Humans; D012306:Risk; D012307:Risk Factors; D000099194:Semaglutide
chemical_list: D004763:Glucagon-Like Peptides; D000099194:Semaglutide